1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine has been researched along with sb 216763 in 2 studies
Studies (1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine) | Trials (1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine) | Recent Studies (post-2010) (1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine) | Studies (sb 216763) | Trials (sb 216763) | Recent Studies (post-2010) (sb 216763) |
---|---|---|---|---|---|
9 | 0 | 2 | 342 | 0 | 225 |
Protein | Taxonomy | 1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine (IC50) | sb 216763 (IC50) |
---|---|---|---|
G2/mitotic-specific cyclin-B2 | Homo sapiens (human) | 0.55 | |
Cyclin-dependent kinase 1 | Homo sapiens (human) | 0.55 | |
G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 0.55 | |
Cyclin-A2 | Homo sapiens (human) | 0.269 | |
Cyclin-dependent kinase 2 | Homo sapiens (human) | 0.269 | |
Glycogen synthase kinase-3 alpha | Homo sapiens (human) | 0.0477 | |
Glycogen synthase kinase-3 beta | Homo sapiens (human) | 0.0342 | |
Cyclin-A1 | Homo sapiens (human) | 0.269 | |
G2/mitotic-specific cyclin-B3 | Homo sapiens (human) | 0.55 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
2 other study(ies) available for 1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine and sb 216763
Article | Year |
---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |